FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 150 filers reported holding FATE THERAPEUTICS INC in Q4 2019. The put-call ratio across all filers is 0.54 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $158 | -60.3% | 30,000 | -25.0% | 0.00% | -100.0% |
| Q4 2022 | $398 | -100.0% | 40,000 | 0.0% | 0.00% | -66.7% |
| Q3 2022 | $887,000 | +26.9% | 40,000 | +40.6% | 0.00% | +50.0% |
| Q2 2022 | $699,000 | -38.4% | 28,450 | 0.0% | 0.00% | -33.3% |
| Q1 2022 | $1,134,000 | -25.7% | 28,450 | +10.1% | 0.00% | -25.0% |
| Q4 2021 | $1,526,000 | +1.6% | 25,850 | +2.8% | 0.00% | 0.0% |
| Q3 2021 | $1,502,000 | -62.4% | 25,150 | -44.3% | 0.00% | -66.7% |
| Q2 2021 | $3,994,000 | +77.5% | 45,150 | +49.8% | 0.01% | +71.4% |
| Q1 2021 | $2,250,000 | -20.2% | 30,150 | 0.0% | 0.01% | -36.4% |
| Q4 2020 | $2,819,000 | +199.9% | 30,150 | +24.8% | 0.01% | +175.0% |
| Q3 2020 | $940,000 | +142.9% | 24,150 | -3.4% | 0.00% | +100.0% |
| Q3 2019 | $387,000 | -62.1% | 25,000 | -50.0% | 0.00% | -60.0% |
| Q2 2019 | $1,022,000 | +248.8% | 50,000 | +100.0% | 0.01% | +150.0% |
| Q4 2018 | $293,000 | – | 25,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARCH Venture Management, LLC | 2,073,190 | $26,599,000 | 26.59% |
| Polaris Venture Management Co. V, L.L.C. | 1,823,186 | $23,391,000 | 24.97% |
| Casdin Capital, LLC | 2,550,000 | $32,717,000 | 5.60% |
| Redmile Group, LLC | 10,359,666 | $132,915,000 | 5.34% |
| Aquilo Capital Management, LLC | 697,096 | $8,944,000 | 4.33% |
| Eversept Partners, LP | 165,000 | $2,116,950 | 1.15% |
| Artal Group S.A. | 2,150,000 | $27,585,000 | 1.02% |
| AlpInvest Partners B.V. | 26,925 | $345,000 | 0.99% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 1,654,865 | $21,232,000 | 0.85% |
| Lisanti Capital Growth, LLC | 142,760 | $1,832,000 | 0.74% |